Limited distribution networks stifle competition in the generic and biosimilar drug industries

Research output: Contribution to journalReview article

Abstract

A limited distribution network (LDN) restricts the distribution channel for a pharmaceutical drug to 1 or a very small number of distributors. This strategy may allow for more effective allocation of drugs in shortage and is purported to help ensure the safe distribution of high-risk drugs to small patient populations. However, in recent years, some drug companies, including Turing Pharmaceuticals, have used LDNs to prevent generic and biosimilar companies from accessing samples of drug products necessary to perform testing required by the FDA for generic and biosimilar drug applications. LDNs also hamper provider access to pharmaceuticals and facilitate price gouging. This paper synthesizes existing knowledge on the misuse of LDNs to thwart competition, clarifies the relationship between limited distribution and the FDA Risk Evaluation and Mitigation Strategies, discusses proposed federal legislation under consideration to address this issue, and offers several policy options to remedy this anticompetitive practice, including authorizing the FDA to require the sale of approved drug products to generic and biosimilar drug developers.

Original languageEnglish (US)
Pages (from-to)e122-e127
JournalAmerican Journal of Managed Care
Volume24
Issue number4
StatePublished - Apr 1 2018

Fingerprint

Biosimilar Pharmaceuticals
Stifle
Generic Drugs
Drug Industry
Pharmaceutical Preparations
Legislation

ASJC Scopus subject areas

  • Health Policy

Cite this

Limited distribution networks stifle competition in the generic and biosimilar drug industries. / Karas, Laura; Shermock, Kenneth M; Proctor, Celia; Socal, Mariana P; Anderson, Gerard F.

In: American Journal of Managed Care, Vol. 24, No. 4, 01.04.2018, p. e122-e127.

Research output: Contribution to journalReview article

@article{7909489c7a4a420baa83f862739282b5,
title = "Limited distribution networks stifle competition in the generic and biosimilar drug industries",
abstract = "A limited distribution network (LDN) restricts the distribution channel for a pharmaceutical drug to 1 or a very small number of distributors. This strategy may allow for more effective allocation of drugs in shortage and is purported to help ensure the safe distribution of high-risk drugs to small patient populations. However, in recent years, some drug companies, including Turing Pharmaceuticals, have used LDNs to prevent generic and biosimilar companies from accessing samples of drug products necessary to perform testing required by the FDA for generic and biosimilar drug applications. LDNs also hamper provider access to pharmaceuticals and facilitate price gouging. This paper synthesizes existing knowledge on the misuse of LDNs to thwart competition, clarifies the relationship between limited distribution and the FDA Risk Evaluation and Mitigation Strategies, discusses proposed federal legislation under consideration to address this issue, and offers several policy options to remedy this anticompetitive practice, including authorizing the FDA to require the sale of approved drug products to generic and biosimilar drug developers.",
author = "Laura Karas and Shermock, {Kenneth M} and Celia Proctor and Socal, {Mariana P} and Anderson, {Gerard F}",
year = "2018",
month = "4",
day = "1",
language = "English (US)",
volume = "24",
pages = "e122--e127",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "4",

}

TY - JOUR

T1 - Limited distribution networks stifle competition in the generic and biosimilar drug industries

AU - Karas, Laura

AU - Shermock, Kenneth M

AU - Proctor, Celia

AU - Socal, Mariana P

AU - Anderson, Gerard F

PY - 2018/4/1

Y1 - 2018/4/1

N2 - A limited distribution network (LDN) restricts the distribution channel for a pharmaceutical drug to 1 or a very small number of distributors. This strategy may allow for more effective allocation of drugs in shortage and is purported to help ensure the safe distribution of high-risk drugs to small patient populations. However, in recent years, some drug companies, including Turing Pharmaceuticals, have used LDNs to prevent generic and biosimilar companies from accessing samples of drug products necessary to perform testing required by the FDA for generic and biosimilar drug applications. LDNs also hamper provider access to pharmaceuticals and facilitate price gouging. This paper synthesizes existing knowledge on the misuse of LDNs to thwart competition, clarifies the relationship between limited distribution and the FDA Risk Evaluation and Mitigation Strategies, discusses proposed federal legislation under consideration to address this issue, and offers several policy options to remedy this anticompetitive practice, including authorizing the FDA to require the sale of approved drug products to generic and biosimilar drug developers.

AB - A limited distribution network (LDN) restricts the distribution channel for a pharmaceutical drug to 1 or a very small number of distributors. This strategy may allow for more effective allocation of drugs in shortage and is purported to help ensure the safe distribution of high-risk drugs to small patient populations. However, in recent years, some drug companies, including Turing Pharmaceuticals, have used LDNs to prevent generic and biosimilar companies from accessing samples of drug products necessary to perform testing required by the FDA for generic and biosimilar drug applications. LDNs also hamper provider access to pharmaceuticals and facilitate price gouging. This paper synthesizes existing knowledge on the misuse of LDNs to thwart competition, clarifies the relationship between limited distribution and the FDA Risk Evaluation and Mitigation Strategies, discusses proposed federal legislation under consideration to address this issue, and offers several policy options to remedy this anticompetitive practice, including authorizing the FDA to require the sale of approved drug products to generic and biosimilar drug developers.

UR - http://www.scopus.com/inward/record.url?scp=85044976064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044976064&partnerID=8YFLogxK

M3 - Review article

C2 - 29668215

AN - SCOPUS:85044976064

VL - 24

SP - e122-e127

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 4

ER -